Back to search results

ALXN2420 for Acromegaly

This study is testing a new drug called ALXN2420 for people with acromegaly, a condition where your body makes too much growth hormone. You might be able to join if you are between 18 and 80 years old, have a confirmed diagnosis of acromegaly, and are already taking a stable dose of long-acting somatostatin analogs (like octreotide or lanreotide LAR) for at least six months. Participants will receive either ALXN2420 or a placebo (an inactive substance) as an injection, in addition to their current somatostatin analog therapy. The main goal is to see if ALXN2420 can lower levels of IGF-1 (insulin-like growth factor 1), a hormone that is high in people with acromegaly, after 15 weeks of treatment. The current status of this study is unclear.

Study design
This interventional study plans to enroll 60 participants. It compares ALXN2420 to a placebo, both given as subcutaneous injections.
What's involved
Participants will receive injections of either ALXN2420 or a placebo. The primary endpoint is measured at Week 15.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at Week 15, indicating at least 15 weeks of participation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07037420

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Terminated
PHASE2Ages 18–80InterventionalTreatment
Alexion Pharmaceuticals, Inc.
~8 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:ALXN2420Placebo

At a glance

Recruiting sites
0 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage Change From Baseline in Serum IGF-1 Level at Week 15
Measured over Baseline, Week 15

Conditions

Acromegaly

Explore related trials

AcromegalyIGF1 Gene

Where it's being run

6 sites across 5 states
Lithuania2
California1
Michigan1
Italy1
Romania1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented diagnosis of acromegaly, that is, historically documented evidence of a GH-secreting pituitary adenoma based on MRI or pathology report
Must be receiving maximum, or maximally tolerated dose per treating physician judgment, of long-acting SSAs (octreotide or lanreotide LAR) and meet both of the following:
Must be a partial responder to SSAs defined as \> 20% relative IGF 1 reduction during the course of SSA therapy
Serum IGF-1 levels \> 1.3 to 5\*ULN inclusive, as assessed at a central laboratory and adjusted for age and sex, based on average of 2 consecutive values obtained during the Screening Period and obtained ≥ 7 days apart

Exclusion

Had surgery for pituitary adenoma within the last 6 months before Day 1 or planning to receive surgery for pituitary adenoma during the study
Pituitary adenoma that, per Investigator's judgment, is worsening as assessed by pituitary/sellar MRI or computed tomography scan obtained ≤ 6 months prior to screening
Pituitary adenoma causing compression of the chiasm
Clinical evidence of symptomatic hyperprolactinemia that would necessitate treatment with dopamine agonists
Known hypothyroidism or hypocortisolism not adequately treated with a stable dose of thyroid or glucocorticoid hormone replacement therapy for ≥ 3 months prior to Screening
Active, clinically significant cardiac disease as judged by the Investigator
History of unstable angina, stroke, or acute myocardial infarction ≤ 3 months prior to screening
Known uncontrolled type 2 diabetes (HbA1c \> 10%)
Active malignant disease ≤ 2 years prior to screening with exception of basal and squamous cell carcinoma of the skin
Received any type of fractionated radiotherapy or a second surgical adenectomy for pituitary adenoma within the last 3 years (5 years for conventional radiation) before starting treatment and/or are planning to receive radiotherapy or a second surgical adenectomy during the study
Received pegvisomant ≤ 8 weeks prior to screening
Received dopamine agonists ≤ 4 weeks prior to screening
Received pasireotide LAR ≤ 4 months prior to screening
Clinically significant renal or hepatic disease at the time of screening, as judged by the Investigator
eGFR (CKD-EPI formula) \< 30 mL/minute/1.73 m\^2 documented based on recent value (\< 3 months prior to randomization)
Clinically significant abnormal values for hematology, biochemistry, coagulation, or urinalysis, as judged by the Investigator, including, but not limited to, total bilirubin \> 1.5\*ULN (except if in free bilirubin linked to a known Gilbert Syndrome) or AST, ALT, or alkaline phosphatase \> 2\*ULN

What this trial measures

  • Percentage Change From Baseline in Serum IGF-1 Level at Week 15Baseline, Week 15